Martinsried, Germany – November 26, 2024 – Eisbach Bio GmbH, a pioneering precision oncology company, is pleased to announce the receipt of a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This prestigious grant of US$4.75 million will support the clinical development of Eisbach’s first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, a chromatin remodeling enzyme and helicase that represents the mo

MARTINSRIED, Germany, September 16, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, today announced that the first patient has been dosed in Module 1 of the ongoing Phase 1/2 MATCH clinical trial (NCT06525298) investigating the small molecule ALC1 inhibitor EIS-12656 in solid tumors. In this trial, Eisbach seeks to assess the safety, pharmacokinetics, pharm

Munich, 18.07.2024 : Eisbach Bio GmbH is set to train the next generation of scientists in the metabolic regulation of genome function through the innovative project NUCLEAR. Coordinated by the Josep Carreras Leukaemia Research Institute near Barcelona, Spain, this network will guide 17 doctoral candidates to become world-class experts and provide new insights at the interface of metabolism and genome regulation, a topic highly relevant to stem cell biology, obesity and cance

MARTINSRIED, Germany, May 24, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, has announced completion and Phase I topline results of EIS-10700. The safety, tolerability and pharmacokinetics of EIS-10700 were investigated in a first-in-human, open label, single center, single dose escalation Phase I study in Germany. Due to the excellent safety profile obta

MARTINSRIED, Germany, May 6, 2024 – Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality, has announced United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for EIS-12656, a small molecule inhibiting the chromatin helicase ALC1 (CHD1L). EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-re

MARTINSRIED, Germany and HOUSTON, Texas, March 21, 2024 –  Eisbach Bio GmbH (Eisbach), a clinical-stage biotechnology company pioneering a new class of cancer medicines leveraging synthetic lethality to target specific proteins that are essential for the survival of cancer cells, and Cancer Focus Fund, LP , a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) to provide funding and clinical expertise to a